Akimitsu Maeda1,2, Hitoshi Ando2, Takashi Ura3, Kei Muro3, Masahiro Aoki4, Ken Saito5, Eisaku Kondo5, Shinji Takahashi6, Yuko Ito6, Yasunari Mizuno6, Akio Fujimura2. 1. Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan m.akimitsu@aichi-cc.jp. 2. Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, Japan. 3. Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. 4. Division of Molecular Pathology, Aichi Cancer Center Research Institute, Nagoya, Japan. 5. Division of Molecular and Cellular Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. 6. Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan.
Abstract
BACKGROUND/AIM: We investigated whether measuring the excretion of each acute kidney injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and evaluated the most appropriate AKI marker in patients treated with CDDP. PATIENTS AND METHODS: We measured NAG, Kim-1, and NGAL in urinary samples of 40 cancer patients treated with chemotherapy on day 1 (before chemotherapy), day 2, and day 5 after treatment; serum creatinine (sCr) was compared on days 7 and 28 after CDDP administration vs. baseline. RESULTS: NAG, Kim-1, and NGAL excretion (creatinine corrected) were not significantly elevated 5 days after receiving chemotherapy in the non-CDDP chemotherapy group. Conversely, all markers were significantly higher 5 days after receiving chemotherapy in the CDDP group when compared to baseline. CONCLUSION: Urinary NAG, Kim-1, and NGAL can detect renal injury more sensitively than sCr. Copyright
BACKGROUND/AIM: We investigated whether measuring the excretion of each acute kidney injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and evaluated the most appropriate AKI marker in patients treated with CDDP. PATIENTS AND METHODS: We measured NAG, Kim-1, and NGAL in urinary samples of 40 cancerpatients treated with chemotherapy on day 1 (before chemotherapy), day 2, and day 5 after treatment; serum creatinine (sCr) was compared on days 7 and 28 after CDDP administration vs. baseline. RESULTS:NAG, Kim-1, and NGAL excretion (creatinine corrected) were not significantly elevated 5 days after receiving chemotherapy in the non-CDDP chemotherapy group. Conversely, all markers were significantly higher 5 days after receiving chemotherapy in the CDDP group when compared to baseline. CONCLUSION: Urinary NAG, Kim-1, and NGAL can detect renal injury more sensitively than sCr. Copyright
Authors: Erika Bíró; István Szegedi; Csongor Kiss; Anna V Oláh; Mark Dockrell; Robert G Price; Tamás Szabó Journal: BMC Pediatr Date: 2022-07-20 Impact factor: 2.567
Authors: Eryk Latoch; Katarzyna Konończuk; Katarzyna Taranta-Janusz; Katarzyna Muszyńska-Rosłan; Edyta Szymczak; Anna Wasilewska; Maryna Krawczuk-Rybak Journal: Cancer Chemother Pharmacol Date: 2020-10-14 Impact factor: 3.333